Alivus Life Sciences: Business Overview & Financial Analysis
Alivus Life Sciences (formerly known as Glenmark Life Sciences) is a leading Indian developer and manufacturer of high-value, non-commoditised active pharmaceutical ingredients (APIs). Promoted by Nirma following its acquisition of a controlling stake, the enterprise specializes in chronic and sub-chronic therapeutic areas including cardiovascular, central nervous system, pain management, diabetes, anti-infectives, and oncology. Operating state-of-the-art manufacturing plants and R&D centers across India, Alivus supplies active ingredients to leading global generic pharmaceutical companies and offers custom development and manufacturing services (CDMO) across regulated and emerging international markets.
Therapy Segment Revenue Breakdown of Alivus Life Sciences (FY2026)
Alivus structures its API product portfolio around specialized chronic and sub-chronic therapeutic categories.
- Cardiovascular (CVS) Therapy Share – 34.2% of Operating Revenue
- Central Nervous System (CNS) Therapy Share – 24.5% of Operating Revenue
- Diabetes & Metabolic Disorders Share – 15.2% of Operating Revenue
- Pain Management & Anti-Infectives Share – 14.8% of Operating Revenue
- Oncology & Other Specialty Therapies Share – 11.3% of Operating Revenue
- Total Consolidated Revenue from Operations (FY2026) – Rs 2,380.50 crore (+9.2% YoY)
Cardiovascular and CNS therapy segments form the primary revenue backbone, driving consistent top-line growth. High-margin oncology APIs and chronic diabetes molecules expand product realisations across regulated markets.
Geographic Revenue Mix of Alivus Life Sciences (FY2026)
Alivus exports active pharmaceutical ingredients to generic drug manufacturers across major global regulated and emerging markets.
- Europe Geography Share – 32.5% of Total Revenue
- India Domestic Market Share – 28.0% of Total Revenue
- North America Geography Share – 22.2% of Total Revenue
- Rest of the World (RoW) & LATAM Share – 17.3% of Total Revenue
- Regulated Markets Contribution Share – 72.5% of Total Revenue
Regulated markets in Europe and North America contribute nearly three-fourths of total turnover, reflecting high quality compliance. Domestic API dispatches in India supply leading formulation exporters and domestic drug manufacturers.
Business Model Revenue Split of Alivus Life Sciences (FY2026)
Alivus balances its core generic API manufacturing business with specialized CDMO contract services for global pharmaceutical innovators.
- Generic Active Pharmaceutical Ingredients (APIs) Business – 92.5% of Total Revenue
- Custom Development & Manufacturing Services (CDMO) – 7.5% of Total Revenue
- Total Commercialised API Product Portfolio – 150+ active commercial molecules
- Cumulative DMF / CEP Filings Base – 500+ global regulatory drug master files
Generic API manufacturing generates the vast majority of operational turnover, supported by a portfolio of over 150 commercial molecules. The CDMO vertical provides contract synthesis and process development for multinational pharmaceutical clients.
Manufacturing Infrastructure & Regulatory Approvals of Alivus Life Sciences (FY2026)
Alivus operates four manufacturing complexes equipped with synthetic reactors, containment suites, and automated quality control laboratories.
- Operational Manufacturing Facilities Base – 4 manufacturing plants in India
- Manufacturing Plant Locations – Ankleshwar (Gujarat), Dahej (Gujarat), Mohol (Maharashtra), and Kurkumbh (Maharashtra)
- Total Annual Installed Reactor Capacity – 1,180+ Kilo Litres (KL)
- Global Regulatory Compliance Approvals – USFDA, PMDA (Japan), EDQM (Europe), COFEPRIS (Mexico), and MFDS (South Korea)
- USFDA Audit Status – All 4 manufacturing plants successfully inspected with zero Form 483 observations
Manufacturing complexes operate under stringent global regulatory standards, with all facilities holding USFDA and EDQM approvals. Fully integrated R&D centers in Mahape and Ankleshwar support process chemistry and DMF filing pipelines.
Latest Quarterly Financial Performance of Alivus Life Sciences (Q1 FY2027)
Alivus recorded top-line revenue expansion and strong operating profit margins during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 612.40 crore (+10.5% YoY)
- Consolidated Operating EBITDA – Rs 185.20 crore (+12.8% YoY)
- Operating EBITDA Margin – 30.24% (+62 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 128.50 crore (+15.2% YoY)
- Board Recommended Interim Dividend – Disclosed as per capital distribution policy
First-quarter operating revenue rose 10.5% year-on-year to Rs 612.40 crore, supported by generic API volume growth in Europe and North America. Consolidated Net Profit After Tax reached Rs 128.50 crore, while operating EBITDA margins expanded to 30.24%.
Consolidated Annual Financial Performance of Alivus Life Sciences (FY2026)
Alivus delivered full-year turnover expansion and operating profit growth for full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 2,380.50 crore (+9.2% YoY)
- Full Year Operating EBITDA – Rs 712.80 crore (+11.5% YoY)
- Full Year Operating EBITDA Margin – 29.94% (+62 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 485.20 crore (+14.2% YoY)
- Return on Capital Employed (ROCE) – 28.5%
Full-year operating turnover crossed Rs 2,380 crore in FY2026, as consolidated Net Profit After Tax expanded 14.2% to Rs 485.20 crore. Financial performance was supported by chronic therapy volume gains, CDMO project execution, and process efficiency.
Balance Sheet Structure & Capital Health Ratios of Alivus Life Sciences (Q1 FY2027)
Alivus operates a zero-debt capital structure backed by strong operating cash flow generation and liquid surplus reserves.
- Debt to Equity Ratio – Net Cash Positive / Zero Debt (0.00x)
- Total Cash, Bank Balances & Surplus Investments – Rs 850.00 crore
- Total Consolidated Net Worth Base – Rs 2,650.00 crore
- Return on Equity (ROE) – 18.8%
- Working Capital Cycle – 115 days
The enterprise closed Q1 FY2027 with zero external financial debt and Rs 850.00 crore in liquid surplus reserves. High capital efficiency generated a Return on Capital Employed of 28.5%, funding internal facility expansions without debt reliance.
Capital Expenditure & Solapur Greenfield Expansion Roadmap of Alivus Life Sciences (FY2027–FY2028)
Alivus executes capital allocation outlays to construct a greenfield API manufacturing plant at Solapur and debottleneck existing units.
- Total Planned Multi-Year Capex Outlay – Rs 600–700 crore over FY2027–FY2028
- Solapur Greenfield Plant Outlay – 1,000 KL reactor capacity greenfield project at Chincholi (Solapur, Maharashtra)
- Solapur Phase-1 Commissioning Target – 200 KL capacity addition targeted by end of FY2027
- High-Potency API (HPAPI) Unit Outlay – Dedicated containment facility for oncology API synthesis at Dahej
- Funding Method – 100% funded through internal operational cash accruals and cash reserves
Annual capital expenditure is budgeted to construct the 1,000 KL Solapur greenfield plant and expand high-potency API containment lines at Dahej. Internal cash accruals fund all planned facility expansions without debt additions.
Strategic Outlook & Management Commentary of Alivus Life Sciences (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on chronic API market share gains, CDMO scaling, and Solapur commissioning.
- Management targets achieving a 12%–15% top-line revenue CAGR over the FY2027–FY2029 period.
- Operating EBITDA margins are guided to sustain within the 29.0%–31.0% corridor through high-margin molecule execution.
- CDMO vertical revenue contribution is targeted to expand toward 12%–15% of total turnover over the next 3 years.
- New molecule filings will prioritize complex synthetic APIs in diabetes, oncology, and central nervous system therapies.
- Capital allocation strategy will maintain a debt-free balance sheet while funding Solapur greenfield construction.
Management anticipates global generic drug adoption and supply chain diversification to drive active ingredient demand. Operational focus centers on commissioning Phase-1 of the Solapur greenfield facility, expanding CDMO contracts, and maintaining strong balance sheet health.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Alivus Life Sciences Q1 FY2027 Consolidated Financial Results Disclosures (July/August 2026)
- Alivus Life Sciences Q4 & Full Year FY2026 Consolidated Financial Results Disclosures (May 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Alivus Life Sciences
- Ticker Finology Alivus Life Sciences Page
Disclaimer
The information presented above on Alivus Life Sciences has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Alivus Life Sciences page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.